Senti Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 48
- Market Cap
- $12.5M
- Introduction
Senti Biosciences, Inc. It was incorporated in Delaware on March 1, 2021. The company aims to design genetic circuits to improve the intelligence of cells and gene therapy to improve its effectiveness, accuracy and persistence in the treatment of a wide range of diseases that cannot be solved by traditional drugs. The company's synthetic biology platform uses ready-made chimeric antigen receptor natural killer cells and is equipped with these genetic circuit technologies for particularly challenging liquid and solid tumor indications. The company's leading projects include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated or + non-ready-made CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while preserving healthy bone marrow. SENTI-301 is an off-the-shelf CAR-NK cell therapy for the treatment of hepatocellular carcinoma. The company has also demonstrated the breadth of its genetic circuits in ways other than oncology and diseases, and has partnered with Spark and BlueRock to advance these capabilities.
Senti Bio's Logic-Gated CAR-NK Cell Therapy Shows Promising Results in AML Clinical Trial
Senti Biosciences presented positive preliminary data from its Phase 1 trial of SENTI-202, showing 5 of 7 evaluable patients with relapsed/refractory AML achieved objective responses, including 4 complete remissions that were all MRD-negative.
Novel "Off-the-Shelf" CAR NK Cell Therapy Shows Complete Remission in Relapsed AML Patients
SENTI-202, a first-in-class CAR NK cell therapy using innovative logic-gating technology, achieved complete remission in four of seven evaluable patients with relapsed/refractory acute myeloid leukemia.
Senti Bio Reports Promising Early Results for Gene Circuit CAR-NK Cell Therapy in Relapsed/Refractory AML
Senti Bio's SENTI-202, a gene circuit-enabled CAR-NK cell therapy, achieved MRD-negative complete remission in 2 of 3 relapsed/refractory AML patients at the lowest dose level in its Phase 1 trial, with both patients maintaining remission.
Over 120 Pipeline Therapies Target Acute Myeloid Leukemia as Research Intensifies
DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer.
NK Cell Therapy Market Poised for Significant Growth with Innovative Pipeline Developments
The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034.